The predicted impact of private sector MMR vaccination on the burden of Congenital Rubella Syndrome
In many developing countries, Measles–Mumps–Rubella (MMR) vaccine is available through the private but not the public sectors, and there is no systematic rubella vaccination among adult women. In this paper, we extend previous modeling studies to demonstrate that in developing countries with a mediu...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2003-06, Vol.21 (21), p.2708-2719 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2719 |
|---|---|
| container_issue | 21 |
| container_start_page | 2708 |
| container_title | Vaccine |
| container_volume | 21 |
| creator | Vynnycky, E. Gay, N.J. Cutts, F.T. |
| description | In many developing countries, Measles–Mumps–Rubella (MMR) vaccine is available through the private but not the public sectors, and there is no systematic rubella vaccination among adult women. In this paper, we extend previous modeling studies to demonstrate that in developing countries with a medium–high force of infection (200–400/1000 per year), current levels of private sector MMR coverage ( |
| doi_str_mv | 10.1016/S0264-410X(03)00229-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73363111</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X03002299</els_id><sourcerecordid>18776540</sourcerecordid><originalsourceid>FETCH-LOGICAL-c516t-8789af6af9953caa756b1eedd689e74eb6c0e652ffe70fd9f29d0004fc9d7adb3</originalsourceid><addsrcrecordid>eNqFkVFrFDEQx4Mo9qx-BCUgin1YTTabZPMkcqgVWoS2gm8hm0w0ZTc5k92DfvvmekcLvhQCA-H3H2bmh9BrSj5SQsWnS9KKruko-f2BsBNC2lY16gla0V6ypuW0f4pW98gRelHKNSGEM6qeoyPaStUL0q-QvfoLeJPBBTuDw2HaGDvj5Otf2JoZcAE7p4zPzy_w1lgboplDiri-uSaHJTuIO36d4h-IYTYjvlgGGEeDL2-iy2mCl-iZN2OBV4d6jH59-3q1Pm3Ofn7_sf5y1lhOxdz0slfGC-OV4swaI7kYKIBzolcgOxiEJSB46z1I4p3yrXJ1pc5b5aRxAztG7_d9Nzn9W6DMegrF7kaJkJaiJWOCUUofBesNpeAdqeDb_8DrtORYl9C0U0JwWV1Uiu8pm1MpGbyux5tMvtGU6J0sfSdL70xowvSdLK1q7s2h-zJM4B5SBzsVeHcATLFm9NlEG8oD1_WCq05U7vOeg3rdbYCsiw0QbbWaqz7tUnhklFsZWLFr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1496657101</pqid></control><display><type>article</type><title>The predicted impact of private sector MMR vaccination on the burden of Congenital Rubella Syndrome</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Vynnycky, E. ; Gay, N.J. ; Cutts, F.T.</creator><creatorcontrib>Vynnycky, E. ; Gay, N.J. ; Cutts, F.T.</creatorcontrib><description>In many developing countries, Measles–Mumps–Rubella (MMR) vaccine is available through the private but not the public sectors, and there is no systematic rubella vaccination among adult women. In this paper, we extend previous modeling studies to demonstrate that in developing countries with a medium–high force of infection (200–400/1000 per year), current levels of private sector MMR coverage (<60%) would lead to increases in the incidence of Congenital Rubella Syndrome (CRS) both among unvaccinated individuals and the general population even when mixing between vaccinated and unvaccinated individuals is fairly minimal. Our findings highlight the need for countries to establish surveillance of trends in susceptibility to rubella and CRS incidence and perhaps introduce rubella vaccination among women of child-bearing age.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/S0264-410X(03)00229-9</identifier><identifier>PMID: 12798608</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adult ; Autism ; Biological and medical sciences ; Children & youth ; Congenital Rubella Syndrome ; Developing Countries ; Female ; Human viral diseases ; Humans ; Immunization Programs ; Infectious diseases ; LDCs ; Male ; Mathematical model ; Measles ; Measles-Mumps-Rubella Vaccine - therapeutic use ; Medical sciences ; MMR vaccination ; Mumps ; Private Sector ; Rubella Syndrome, Congenital - epidemiology ; Rubella Syndrome, Congenital - prevention & control ; Time Factors ; Transmission dynamics ; Tropical medicine ; Vaccination ; Vaccines ; Viral diseases ; Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye</subject><ispartof>Vaccine, 2003-06, Vol.21 (21), p.2708-2719</ispartof><rights>2003 Elsevier Science Ltd</rights><rights>2003 INIST-CNRS</rights><rights>Copyright Elsevier Limited Jun 20, 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c516t-8789af6af9953caa756b1eedd689e74eb6c0e652ffe70fd9f29d0004fc9d7adb3</citedby><cites>FETCH-LOGICAL-c516t-8789af6af9953caa756b1eedd689e74eb6c0e652ffe70fd9f29d0004fc9d7adb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X03002299$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14865946$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12798608$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vynnycky, E.</creatorcontrib><creatorcontrib>Gay, N.J.</creatorcontrib><creatorcontrib>Cutts, F.T.</creatorcontrib><title>The predicted impact of private sector MMR vaccination on the burden of Congenital Rubella Syndrome</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>In many developing countries, Measles–Mumps–Rubella (MMR) vaccine is available through the private but not the public sectors, and there is no systematic rubella vaccination among adult women. In this paper, we extend previous modeling studies to demonstrate that in developing countries with a medium–high force of infection (200–400/1000 per year), current levels of private sector MMR coverage (<60%) would lead to increases in the incidence of Congenital Rubella Syndrome (CRS) both among unvaccinated individuals and the general population even when mixing between vaccinated and unvaccinated individuals is fairly minimal. Our findings highlight the need for countries to establish surveillance of trends in susceptibility to rubella and CRS incidence and perhaps introduce rubella vaccination among women of child-bearing age.</description><subject>Adult</subject><subject>Autism</subject><subject>Biological and medical sciences</subject><subject>Children & youth</subject><subject>Congenital Rubella Syndrome</subject><subject>Developing Countries</subject><subject>Female</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunization Programs</subject><subject>Infectious diseases</subject><subject>LDCs</subject><subject>Male</subject><subject>Mathematical model</subject><subject>Measles</subject><subject>Measles-Mumps-Rubella Vaccine - therapeutic use</subject><subject>Medical sciences</subject><subject>MMR vaccination</subject><subject>Mumps</subject><subject>Private Sector</subject><subject>Rubella Syndrome, Congenital - epidemiology</subject><subject>Rubella Syndrome, Congenital - prevention & control</subject><subject>Time Factors</subject><subject>Transmission dynamics</subject><subject>Tropical medicine</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Viral diseases</subject><subject>Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkVFrFDEQx4Mo9qx-BCUgin1YTTabZPMkcqgVWoS2gm8hm0w0ZTc5k92DfvvmekcLvhQCA-H3H2bmh9BrSj5SQsWnS9KKruko-f2BsBNC2lY16gla0V6ypuW0f4pW98gRelHKNSGEM6qeoyPaStUL0q-QvfoLeJPBBTuDw2HaGDvj5Otf2JoZcAE7p4zPzy_w1lgboplDiri-uSaHJTuIO36d4h-IYTYjvlgGGEeDL2-iy2mCl-iZN2OBV4d6jH59-3q1Pm3Ofn7_sf5y1lhOxdz0slfGC-OV4swaI7kYKIBzolcgOxiEJSB46z1I4p3yrXJ1pc5b5aRxAztG7_d9Nzn9W6DMegrF7kaJkJaiJWOCUUofBesNpeAdqeDb_8DrtORYl9C0U0JwWV1Uiu8pm1MpGbyux5tMvtGU6J0sfSdL70xowvSdLK1q7s2h-zJM4B5SBzsVeHcATLFm9NlEG8oD1_WCq05U7vOeg3rdbYCsiw0QbbWaqz7tUnhklFsZWLFr</recordid><startdate>20030620</startdate><enddate>20030620</enddate><creator>Vynnycky, E.</creator><creator>Gay, N.J.</creator><creator>Cutts, F.T.</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20030620</creationdate><title>The predicted impact of private sector MMR vaccination on the burden of Congenital Rubella Syndrome</title><author>Vynnycky, E. ; Gay, N.J. ; Cutts, F.T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c516t-8789af6af9953caa756b1eedd689e74eb6c0e652ffe70fd9f29d0004fc9d7adb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Autism</topic><topic>Biological and medical sciences</topic><topic>Children & youth</topic><topic>Congenital Rubella Syndrome</topic><topic>Developing Countries</topic><topic>Female</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunization Programs</topic><topic>Infectious diseases</topic><topic>LDCs</topic><topic>Male</topic><topic>Mathematical model</topic><topic>Measles</topic><topic>Measles-Mumps-Rubella Vaccine - therapeutic use</topic><topic>Medical sciences</topic><topic>MMR vaccination</topic><topic>Mumps</topic><topic>Private Sector</topic><topic>Rubella Syndrome, Congenital - epidemiology</topic><topic>Rubella Syndrome, Congenital - prevention & control</topic><topic>Time Factors</topic><topic>Transmission dynamics</topic><topic>Tropical medicine</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Viral diseases</topic><topic>Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vynnycky, E.</creatorcontrib><creatorcontrib>Gay, N.J.</creatorcontrib><creatorcontrib>Cutts, F.T.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vynnycky, E.</au><au>Gay, N.J.</au><au>Cutts, F.T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The predicted impact of private sector MMR vaccination on the burden of Congenital Rubella Syndrome</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2003-06-20</date><risdate>2003</risdate><volume>21</volume><issue>21</issue><spage>2708</spage><epage>2719</epage><pages>2708-2719</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>In many developing countries, Measles–Mumps–Rubella (MMR) vaccine is available through the private but not the public sectors, and there is no systematic rubella vaccination among adult women. In this paper, we extend previous modeling studies to demonstrate that in developing countries with a medium–high force of infection (200–400/1000 per year), current levels of private sector MMR coverage (<60%) would lead to increases in the incidence of Congenital Rubella Syndrome (CRS) both among unvaccinated individuals and the general population even when mixing between vaccinated and unvaccinated individuals is fairly minimal. Our findings highlight the need for countries to establish surveillance of trends in susceptibility to rubella and CRS incidence and perhaps introduce rubella vaccination among women of child-bearing age.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>12798608</pmid><doi>10.1016/S0264-410X(03)00229-9</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2003-06, Vol.21 (21), p.2708-2719 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73363111 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Autism Biological and medical sciences Children & youth Congenital Rubella Syndrome Developing Countries Female Human viral diseases Humans Immunization Programs Infectious diseases LDCs Male Mathematical model Measles Measles-Mumps-Rubella Vaccine - therapeutic use Medical sciences MMR vaccination Mumps Private Sector Rubella Syndrome, Congenital - epidemiology Rubella Syndrome, Congenital - prevention & control Time Factors Transmission dynamics Tropical medicine Vaccination Vaccines Viral diseases Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye |
| title | The predicted impact of private sector MMR vaccination on the burden of Congenital Rubella Syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T05%3A38%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20predicted%20impact%20of%20private%20sector%20MMR%20vaccination%20on%20the%20burden%20of%20Congenital%20Rubella%20Syndrome&rft.jtitle=Vaccine&rft.au=Vynnycky,%20E.&rft.date=2003-06-20&rft.volume=21&rft.issue=21&rft.spage=2708&rft.epage=2719&rft.pages=2708-2719&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/S0264-410X(03)00229-9&rft_dat=%3Cproquest_cross%3E18776540%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1496657101&rft_id=info:pmid/12798608&rft_els_id=S0264410X03002299&rfr_iscdi=true |